EYE DROP WITH DIFLUPREDNATE FOR MACULAR EDEMA TREATMENT
The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
1 - 10 . (canceled)
11 . A method of treating macular edema in a mammal, comprising instilling an eye drop containing an effective amount of difluprednate to the mammal.
12 . The method according to claim 11 , wherein the macular edema is refractory macular edema.
13 . The method according to claim 11 , wherein the eye drop is an emulsion eye drop.
14 . The method according to claim 11 , wherein the concentration of difluprednate in the eye drop is 0.005-0.1% (w/v).
15 . The method according to claim 11 , wherein the eye drop comprises 0.005-0.1% (w/v) of difluprednate, and castor oil, polysorbate 80, concentrated glycerin, sodium acetate, boric acid, sodium edetate and sorbic acid.
16 . The method according to claim 11 , wherein the concentration of difluprednate in the eye drop is 0.005-0.1% (w/v), and the eye drop is administered for at least 1 week, 4 times per day, in a dose of 30-50 μL per administration.
17 . The method according to claim 11 , wherein the concentration of difluprednate in the eye drop is 0.005-0.1% (w/v), and the eye drop is administered for 1-4 weeks, 4 times per day, in a dose of 30-50 μL per administration.
18 . The method according to claim 11 , wherein the concentration of difluprednate in the eye drop is 0.005-0.1% (w/v), and the eye drop is administered 4 times per day for 4 weeks from the start of the administration and twice per day after 4 weeks, in a dose of 30-50 μL per administration.
19 . The method according to claim 11 , wherein the concentration of difluprednate in the eye drop is 0.005-0.1% (w/v), and the eye drop is administered for not longer than 12 weeks, 4 times per day for 4 weeks from the start of the administration and twice per day after 4 weeks, in a dose of 30-50 μL per administration.
20 . The method according to claim 11 , wherein the concentration of difluprednate in the eye drop is 0.005-0.1% (w/v), and the eye drop is administered for at least 12 weeks, 4 times per day for 4 weeks from the start of the administration and twice per day after 4 weeks, in a dose of 30-50 μL per administration.
21 - 40 . (canceled)